A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Theranos is telling its investors that the company finally reached an agreement to settle a lawsuit by Walgreens Boots Alliance, people familiar with the matter have told The Wall Street Journal. The suit argued that the struggling laboratory start-up had breached the companies' contract.
The Journal reported Wednesday morning that the feud between drugstore chain Walgreens and health tech company Theranos is nearing an end.
Walgreens had, at one point, hosted about 40 Theranos blood-testing centers.
In the suit, Walgreens was seeking to recover the $140 million that the retailer says it put into its partnership with Theranos, including a $40 million convertible-debt note and a separate payment as part of an effort to grow that relationship, the Journal said.
The tentative agreement, as reported by the Journal Wednesday, calls for Theranos to pay Walgreens less than $30 million, people familiar with the matter told the publication. The pact hadn't been completed as of late Tuesday and terms could change, the people also said.
Representatives from Theranos and Walgreens didn't immediately respond to requests from CNBC for comment.
Theranos has come out and said the suits against it were without merit. Meanwhile, Theranos still faces a civil investigation by the Securities and Exchange Commission and a criminal investigation by the Justice Department, according to court filings.
Regulators found problems in early 2016 with Theranos' lab practices, which the regulators said put patients in danger.
Walgreens' relationship with Theranos dates back to 2010. After The Journal first raised questions about Theranos' technology in Oct. 2015, Walgreens said it would end expansion of the partnership.
Earlier this year, Theranos said it settled lawsuits with one of its biggest backers.
The start-up said it reached a confidential settlement with hedge fund Partner Fund Management, which invested more than $96 million in Theranos in 2014.
Partner Fund Management had accused Theranos of securities fraud, alleging that the company had attracted the investment '[t]hrough a series of lies, material misstatements and omissions. "